{"id":"twice-daily-immunosuppression-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Bone marrow suppression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This regimen typically combines multiple immunosuppressive agents administered twice daily to achieve sustained suppression of T-cell and B-cell mediated immune responses. The specific mechanism depends on the constituent drugs, which commonly include calcineurin inhibitors, antiproliferative agents, and/or corticosteroids that work synergistically to prevent graft rejection or control autoimmune disease.","oneSentence":"A twice-daily immunosuppressive regimen reduces immune system activity to prevent organ rejection or manage autoimmune conditions.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:36:08.838Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prevention"},{"name":"Autoimmune disease management"}]},"trialDetails":[{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT04187105","phase":"PHASE2","title":"BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2020-01-27","conditions":"Acute Leukemia, MDS","enrollment":27},{"nctId":"NCT05654922","phase":"PHASE3","title":"Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant","status":"RECRUITING","sponsor":"Renovion, Inc.","startDate":"2023-04-10","conditions":"Pre-Bronchiolitis Obliterans Syndrome","enrollment":100},{"nctId":"NCT04833907","phase":"PHASE1, PHASE2","title":"rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Myrtelle Inc.","startDate":"2021-04-01","conditions":"Canavan Disease","enrollment":24},{"nctId":"NCT04773392","phase":"PHASE4","title":"Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2021-11-23","conditions":"Kidney Transplantation, Kidney Transplant Rejection","enrollment":20},{"nctId":"NCT04678401","phase":"PHASE1","title":"IS-free Treg HaploHCT","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-01-12","conditions":"Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute","enrollment":30},{"nctId":"NCT02711826","phase":"PHASE1, PHASE2","title":"Treg Therapy in Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-09-20","conditions":"Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant","enrollment":32},{"nctId":"NCT04469842","phase":"EARLY_PHASE1","title":"Early Use of Long-acting Tacrolimus in Lung Transplant Recipients","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-12-01","conditions":"Lung Transplant; Complications","enrollment":48},{"nctId":"NCT03555448","phase":"PHASE4","title":"Once Daily Immunosuppression Regimen","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2018-06-04","conditions":"Kidney Transplant; Complications","enrollment":51},{"nctId":"NCT06594133","phase":"","title":"Longitudinal and Cross-sectional Analysis of Pulmonary Microbiota in Lung Transplant Recipients Infected With Nocardia","status":"COMPLETED","sponsor":"Zhibin Xu","startDate":"2023-01-01","conditions":"Nocardia Infections, Lung Transplantation","enrollment":68},{"nctId":"NCT01614665","phase":"PHASE2","title":"A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2012-04-03","conditions":"Heart Transplantation, Kidney Transplantation, Liver Transplantation","enrollment":44},{"nctId":"NCT01371344","phase":"PHASE4","title":"A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients","status":"TERMINATED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2011-06-24","conditions":"Heart Transplantation, Kidney Transplantation, Liver Transplantation","enrollment":47},{"nctId":"NCT01044745","phase":"PHASE2","title":"Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2009-12-10","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":20},{"nctId":"NCT03438773","phase":"PHASE1","title":"Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients","status":"UNKNOWN","sponsor":"California Institute of Renal Research","startDate":"2018-07-11","conditions":"Kidney Transplant; Complications, Kidney Transplant Failure and Rejection","enrollment":50},{"nctId":"NCT01516593","phase":"PHASE2","title":"Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma","status":"COMPLETED","sponsor":"Andres J. M. Ferreri","startDate":"2011-11","conditions":"HIV, Burkitt's Lymphoma","enrollment":19},{"nctId":"NCT05207358","phase":"PHASE4","title":"Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis","status":"RECRUITING","sponsor":"Institutul Clinic Fundeni","startDate":"2022-03-02","conditions":"Lupus Nephritis","enrollment":30},{"nctId":"NCT00185640","phase":"PHASE2","title":"Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Stanford University","startDate":"2003-03","conditions":"Blood Cancer, Leukemia","enrollment":303},{"nctId":"NCT01220856","phase":"PHASE2","title":"Reparixin in Pancreatic Islet Transplantation","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2010-07-28","conditions":"Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus","enrollment":9},{"nctId":"NCT02540395","phase":"NA","title":"Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"Prof. Dr. Petra Reinke","startDate":"2015-03","conditions":"Disorder Related to Renal Transplantation, Effects of Immunosuppressant Therapy","enrollment":184},{"nctId":"NCT01856257","phase":"PHASE2","title":"Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-07","conditions":"Primary Renal Allograft Candidate, Kidney Transplantation","enrollment":71},{"nctId":"NCT02130817","phase":"PHASE4","title":"Belatacept in Kidney Transplantation of Moderately Sensitized Patients","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2014-09-24","conditions":"End Stage Renal Disease, Antibody Mediated Rejection","enrollment":""},{"nctId":"NCT02029638","phase":"PHASE2","title":"BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-01-07","conditions":"Kidney Transplantation","enrollment":4},{"nctId":"NCT03500848","phase":"PHASE2, PHASE3","title":"Sirolimus-based Immunosuppression Treatment Regimen for Liver Transplantation","status":"UNKNOWN","sponsor":"Southern Medical University, China","startDate":"2018-05-01","conditions":"Liver Transplantation","enrollment":130},{"nctId":"NCT01636466","phase":"PHASE3","title":"The Everolimus-Transplant Exit Strategy Trial (E-TEST)","status":"TERMINATED","sponsor":"Ashtar Chami","startDate":"2013-06","conditions":"Kidney Failure, Chronic","enrollment":1},{"nctId":"NCT00445744","phase":"NA","title":"Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2006-12","conditions":"Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)","enrollment":52},{"nctId":"NCT01626092","phase":"NA","title":"Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2012-07-11","conditions":"Lysosomal Storage Disease, Peroxisomal Disorder","enrollment":3},{"nctId":"NCT01884571","phase":"PHASE2","title":"Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Emory University","startDate":"2013-10","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":31},{"nctId":"NCT01436305","phase":"PHASE2","title":"Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-09","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":19},{"nctId":"NCT01328496","phase":"PHASE2","title":"Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2011-06-15","conditions":"Hematologic Malignancies, Disorder Related to Transplantation, Hematopoietic Malignancy","enrollment":14},{"nctId":"NCT01598987","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Renal Function, Liver Transplant","enrollment":56},{"nctId":"NCT00160966","phase":"PHASE4","title":"Impact of Immunosuppressive Regimens on Polyomavirus-related Transplant Nephropathy","status":"COMPLETED","sponsor":"University of Giessen","startDate":"2004-09","conditions":"Polyomavirus Infections","enrollment":108},{"nctId":"NCT00240994","phase":"PHASE2","title":"Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-01","conditions":"Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression","enrollment":35},{"nctId":"NCT00141037","phase":"PHASE1, PHASE2","title":"Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-03","conditions":"Kidney Diseases, Kidney Transplantation, Kidney Transplant","enrollment":130},{"nctId":"NCT01023815","phase":"PHASE3","title":"Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-04","conditions":"de Novo Kidney Transplant Recipients, Renal Transplantation","enrollment":330},{"nctId":"NCT01709604","phase":"","title":"Role of CVVH in Patients With Acute Paraquat Poisoning","status":"COMPLETED","sponsor":"Ai Peng","startDate":"2012-10","conditions":"Poisoning by Paraquat With Undetermined Intent","enrollment":110},{"nctId":"NCT01169701","phase":"PHASE4","title":"24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-08","conditions":"Renal Transplant","enrollment":71},{"nctId":"NCT00282256","phase":"PHASE2","title":"A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-01","conditions":"Liver Transplantation","enrollment":19},{"nctId":"NCT00282243","phase":"PHASE2","title":"A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2003-02","conditions":"Liver Transplantation","enrollment":70},{"nctId":"NCT00282568","phase":"PHASE2","title":"A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-08","conditions":"Kidney Transplantation","enrollment":70},{"nctId":"NCT01609673","phase":"NA","title":"Study of Everolimus in de Novo Renal Transplant Recipients","status":"TERMINATED","sponsor":"Helady Pinheiro, MD, PhD","startDate":"2013-03","conditions":"End Stage Renal Failure With Renal Transplant","enrollment":1},{"nctId":"NCT01875224","phase":"PHASE4","title":"Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression","status":"UNKNOWN","sponsor":"University of Arizona","startDate":"2013-08","conditions":"New Onset Diabetes After Transplant, Kidney Transplantation","enrollment":32},{"nctId":"NCT01276457","phase":"PHASE3","title":"Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-05","conditions":"Transplantation Infection","enrollment":223}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Twice daily immunosuppression regimen","genericName":"Twice daily immunosuppression regimen","companyName":"Washington University School of Medicine","companyId":"washington-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A twice-daily immunosuppressive regimen reduces immune system activity to prevent organ rejection or manage autoimmune conditions. Used for Organ transplant rejection prevention, Autoimmune disease management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}